Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30540043 | 1.00 | USP2 (0.59) | USP2SMN1; SMN2RECQLGPR119EPHX2 | |
| SCHEMBL25365082 | 0.91 | USP2 (0.55) | USP2SMN1; SMN2RECQLGPR119EPHX2 | |
| SCHEMBL20669397 | 0.87 | HPGD (0.48) | USP2SMN1; SMN2RECQLGPR119EPHX2 | |
| SCHEMBL20669370 | 0.86 | HPGD (0.50) | USP2SMN1; SMN2RECQLGPR119EPHX2 | |
| SCHEMBL24746946 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2RECQLGPR119EPHX2 | |
| SCHEMBL24480361 | 0.84 | GPR119 (0.43) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL20669374 | 0.84 | GPR119 (0.43) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL26699680 | 0.84 | GPR119 (0.43) | USP2SMN1; SMN2RECQLGPR119EPHX2 | |
| SCHEMBL31511899 | 0.83 | USP2 (0.51) | USP2SMN1; SMN2RECQLGPR119EPHX2 | |
| SCHEMBL31511898 | 0.83 | USP2 (0.51) | USP2SMN1; SMN2RECQLGPR119EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-15 | — | — | US | disclosed |
| CN-119731156-A | Emopanamide binding protein inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4479384-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | USP2 3261/4885SMN1; SMN2 1668/4885RECQL 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.